8-K: LENSAR Reports Strong Q1 2024 Results with 28% Revenue Growth and Increased Procedure Volume

LENSAR, Inc. announced a 28% increase in total revenue and a 25% increase in procedure volume for the first quarter of 2024, driven by the adoption of its ALLY Adaptive Cataract Treatment System.

Summary

• LENSAR, Inc. reported a strong first quarter for 2024, with total revenue reaching $10.6 million, a 28% increase compared to $8.3 million in the same quarter of 2023.
• The company's procedure volume also saw significant growth, increasing by 25% worldwide and 23% in the U.S., its largest market.
• The installed base of the ALLY Adaptive Cataract Treatment System grew to 65 systems as of March 31, 2024.
• LENSAR's U.S. procedure share increased by 1.5% from the previous quarter, marking the highest single-quarter gain since the launch of ALLY.
• The company's net loss for the quarter was $2.2 million, or ($0.19) per share, an improvement from a net loss of $4.3 million, or ($0.40) per share, in the first quarter of 2023.
• EBITDA for the quarter was ($1.4) million, compared to ($3.5) million in the same period last year, and adjusted EBITDA was ($1.3) million, compared to ($1.8) million.
• As of March 31, 2024, LENSAR had $19.1 million in cash, cash equivalents, and investments, down from $24.6 million at the end of 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, increased procedure volume, and improved financial metrics. While the company is still operating at a loss, the improvements and future outlook are encouraging.

Positives

• The company experienced significant revenue growth of 28% year-over-year.
• Procedure volumes increased substantially, both in the U.S. and worldwide.
• The installed base of ALLY systems is growing, indicating market adoption.
• LENSAR's U.S. procedure share is increasing, demonstrating competitive gains.
• The company's net loss has decreased significantly compared to the same quarter last year.
• Both EBITDA and adjusted EBITDA have improved year-over-year.

Negatives

• The company still reported a net loss of $2.2 million for the quarter.
• Cash, cash equivalents, and investments decreased to $19.1 million from $24.6 million at the end of 2023.
• The company is still operating at a loss, with negative EBITDA and adjusted EBITDA.

Risks

• The company has a history of operating losses and needs to achieve and sustain profitability.
• The company's ability to commercialize the ALLY system and maintain the LENSAR Laser System is subject to regulatory approvals.
• Global macroeconomic conditions could impact the business, financial condition, and results of operations.
• The willingness of patients to pay for the company's products compared to standard procedures is a risk.
• The company's ability to raise additional funds on acceptable terms is uncertain.
• Supply chain disruptions and inflationary pressures could impact the business.
• Competition from companies with more established products and greater resources is a risk.
• The company faces risks associated with marketing, selling, and leasing products in international markets.
• Exposure to credit risk from customers is a potential issue.
• The company's ability to secure adequate coverage or reimbursement for procedures using the ALLY system is a risk.
• Product liability suits could impact the business.
• Government regulations applicable to the company's products and operations pose a risk.
• Risks related to intellectual property and other intellectual property matters exist.

Future Outlook

The company anticipates continued growth in the U.S. and internationally upon receipt of regulatory approvals for the ALLY system, expected later this year.

Management Comments

• Nick Curtis, President and CEO of LENSAR, stated that the company delivered continued 20%+ revenue growth in the first quarter of 2024 due to the recognition of ALLY's advantages.
• Nick Curtis also noted that the company's U.S. procedure share continued to grow, increasing 1.5% in the first quarter from the fourth quarter of 2023.

Industry Context

The announcement reflects a positive trend in the adoption of advanced femtosecond laser technology in cataract surgery, with LENSAR's ALLY system gaining market share. This is in line with the broader industry's move towards more efficient and precise surgical solutions.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, LENSAR's 28% revenue growth and 25% procedure volume increase are strong indicators of market traction compared to industry averages.
• The 1.5% increase in U.S. procedure share is a significant gain, suggesting that LENSAR is effectively competing with established players in the cataract surgery market.
• Companies like Alcon and Johnson & Johnson Vision are major players in the cataract surgery market, and LENSAR's growth suggests it is gaining ground against these larger competitors.
• The adoption rate of the ALLY system, with 65 systems installed, indicates a positive trend compared to the adoption rates of similar new technologies in the medical device industry.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and improved financial metrics positively.
• Employees may be encouraged by the company's growth and market adoption of its products.
• Customers (surgeons and patients) will benefit from the advanced technology and improved surgical outcomes.
• Suppliers may see increased demand for components and materials.
• Creditors may view the company's improved financial performance favorably.

Next Steps

• The company plans to continue to grow both in the U.S. and internationally upon receipt of the regulatory approvals anticipated later this year.
• LENSAR management will host a conference call and live webcast to discuss the first quarter results and provide a business update on May 9, 2024.

Key Dates

Keywords

LENSAR, ALLY Adaptive Cataract Treatment System, Cataract Surgery, Femtosecond Laser, Medical Technology, Procedure Volume, Revenue Growth, EBITDA, Net Loss, Installed Base